Monkey pox: the High Authority for Health specifies the vaccination strategy for first-time vaccinees and children

The HAS recommends administering a dose of vaccine to people at risk, who have been in contact with a patient, as well as children exposed to the virus.

Faced with cases of monkeypox, the High Authority for Health (HAS) recommended on Monday to administer a single dose of vaccine to at-risk contact persons vaccinated against smallpox before 1980, except for immunocompromised people.

In addition, she proposed that the vaccination of children exposed to the virus and likely to develop a severe form of the disease could be considered on a case-by-case basis.

A single dose for already vaccinated at-risk contact cases

In May, the HAS recommended vaccinating adults at high risk of monkeypox.

It was then contacted by the Ministry of Health to specify the vaccination strategy to be implemented around a confirmed case of monkeypox for two population groups: first-time recipients, i.e. people vaccinated against smallpox in childhood, and children.

For the first group, it recommended the administration of a single dose of the Imvanex (Bavarian Nordic) vaccine for at-risk contact persons who had received smallpox vaccination with a first-generation vaccine before 1980, according to its opinion published on Monday. .

In the particular case where the contact persons at risk are immunocompromised, previous vaccination with another smallpox vaccine does not modify the schedule initially recommended in this population, ie three doses of Imvanex.

Vaccination for children at risk

For minors, although the Imvanex vaccine is currently authorized only in adults, several studies concerning other vaccines using the same platform as Imvanex, at higher doses, have demonstrated good tolerance in children. more than four months, underlined the HAS.

She thus recommended that reactive vaccination of child contacts at risk “could be considered, to protect children exposed and possibly more likely to develop severe forms of the disease, in particular the most fragile and the immunocompromised”.

However, in the absence of clinical data on the safety of third-generation vaccines, the HAS recommended that the vaccination of people under the age of 18 “be considered on a case-by-case basis, by specialists only and after a strict evaluation of the benefits. and risks for the minor concerned”.

Leave a Comment